Kazia Therapeutics Limited KZIA
At closeNov 4, 2026, 4:00 PM EST
After hours · Nov 4, 4:00 PM ET
- YTD
- +17.27%
- 1 year
- +5.48%
- Market cap
- 92.33M
- Revenue (ttm)
- 560
- EPS (ttm)
- -6.85
- Shares out
- 4.35M
- YTD return
- +17.27%
- 1-year return
- +5.48%
- Volume
- 238.42K
- Avg volume
- 269.64K
- Open
- 8.27
- Previous close
- 8.08
- Day's range
- 7.74 – 8.54
- 52-week range
- 4.86 – 17.40
- Beta
- 2.08
5D -0.57 (-6.60%)
Key statistics
- Enterprise value
- 1.20B
- PEG ratio
- 0.00
- Price / sales
- 23096.84
- Price / book
- 1.49
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -6.57M
- Total cash
- 3.56M
- Total debt
- 359.30K
- Return on equity
- -186.37%
- Short % of float
- 1.68%
- 50-day average
- 4.90
- 200-day average
- 3.80
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 11, 2023 | HC Wainwright & Co. | up | Neutral | Buy |
| Aug 2, 2022 | Maxim Group | down | Buy | Hold |
| Aug 2, 2022 | HC Wainwright & Co. | down | Buy | Neutral |
| Oct 14, 2021 | Maxim Group | init | — | Buy |
| Jan 5, 2021 | HC Wainwright & Co. | init | — | Buy |
About Kazia Therapeutics Limited
Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Australia
- Website
- kaziatherapeutics.com
News
Kazia Therapeutics Says Two Abstracts Highlighting Paxalisib Tumor And Immune Reprogramming Research Accepted For Poster Presentation At 2026 San Antonio Breast Cancer Symposium 
Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium 
This Kazia Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday - Needham Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $27
Kazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation Conference 
This Equinix Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday 
Guggenheim Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $35 
Leerink Partners Initiates Coverage On Kazia Therapeutics with Outperform Rating, Announces Price Target of $30 - Kazia Therapeutics Announces Sovargen Doses First Participant In Phase 1b/2a Clinical Study Of Paxalisib To Treat Epilepsies
Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
Your note
Sign in to keep a note on KZIA — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| MAI Capital Management | 3.13% | 136,389 | 405.07K | Sep 29, 2024 |
| UBS Group AG | 0.57% | 24,945 | 74.09K | Sep 29, 2024 |
| Morgan Stanley | 0.51% | 22,026 | 65.42K | Sep 29, 2024 |
| Captrust Financial Advisors | 0.35% | 15,265 | 45.34K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.14% | 6,048 | 17.96K | Sep 29, 2024 |
| Jane Street Group, LLC | 0.11% | 4,611 | 13.69K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.03% | 1,478 | 4.39K | Oct 30, 2024 |